Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the ...

Prime Minister Narendra Modi on Thursday unveiled the genome sequencing data of 10,000 Indian nationals, describing the ...

We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look ...

We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Many people believe that as they approach and enter retirement, they should be shedding most or all of their stocks. They assume that since the stock market can be volatile, they should stick with ...

The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...

Learn more about Zhengye Biotechnology Holding Limited's (ZYBT) stock grades for Value and determine whether this Pharmaceuticals stock meets your investment needs.

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...